136 related articles for article (PubMed ID: 35929145)
1. [FDA Premarket Pathways for Combination Products].
Lin Y
Zhongguo Yi Liao Qi Xie Za Zhi; 2022 Jul; 46(4):355-360. PubMed ID: 35929145
[TBL] [Abstract][Full Text] [Related]
2. FDA's misplaced priorities: premarket review under the Family Smoking Prevention and Tobacco Control Act.
Jenson D; Lester J; Berman ML
Tob Control; 2016 May; 25(3):246-53. PubMed ID: 27068243
[TBL] [Abstract][Full Text] [Related]
3. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
4. Assessing risks of changing sterile drug manufacturing sites.
Langille SE; Campbell C
PDA J Pharm Sci Technol; 2010; 64(1):3-10. PubMed ID: 21501998
[TBL] [Abstract][Full Text] [Related]
5. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
6. Medical devices; procedures for premarket notification, premarket approval, classification, performance standards establishment, banning devices, and availability of regulatory hearings--FDA. Final rule.
Fed Regist; 1992 Dec; 57(238):58400-6. PubMed ID: 10123143
[TBL] [Abstract][Full Text] [Related]
7. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
Kim H
Int J Health Policy Manag; 2015 Aug; 4(12):813-21. PubMed ID: 26673465
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of FDA's Review Concerns for Premarket Pathways and Predicate Product Selection of Device-led Combination Products].
Tian J
Zhongguo Yi Liao Qi Xie Za Zhi; 2023 Sep; 47(5):566-570. PubMed ID: 37753899
[TBL] [Abstract][Full Text] [Related]
9. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
[TBL] [Abstract][Full Text] [Related]
10. A decade of direct-to-consumer advertising of prescription drugs.
Donohue JM; Cevasco M; Rosenthal MB
N Engl J Med; 2007 Aug; 357(7):673-81. PubMed ID: 17699817
[TBL] [Abstract][Full Text] [Related]
11. The FDA and Ensuring Safety and Effectiveness of Devices, Biologics, and Technology.
Dubin JR; Ibad H; Cil A; Murray M
J Am Acad Orthop Surg; 2022 Jul; 30(14):658-667. PubMed ID: 35797679
[TBL] [Abstract][Full Text] [Related]
12. We really need to talk: adapting FDA processes to rapid change.
Lykken S
Food Drug Law J; 2013; 68(4):357-99, i. PubMed ID: 24552079
[TBL] [Abstract][Full Text] [Related]
13. Medical Marketing in the United States, 1997-2016.
Schwartz LM; Woloshin S
JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
[TBL] [Abstract][Full Text] [Related]
14. Biological products regulated under Section 351 of the Public Health Services Act; implementation of biologics license; elimination of establishment license and product license--FDA. Proposed rule.
Fed Regist; 1998 Jul; 63(147):40858-71. PubMed ID: 10181717
[TBL] [Abstract][Full Text] [Related]
15. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
16. The road to market implantable drug delivery systems: a review on US FDA's regulatory framework and quality control requirements.
Al-Jawadi S; Capasso P; Sharma M
Pharm Dev Technol; 2018 Dec; 23(10):953-963. PubMed ID: 30084277
[TBL] [Abstract][Full Text] [Related]
17. History and Current Trends in the Electronic Cigarette Retail Marketplace in the United States: 2010-2016.
Cantrell J; Huang J; Greenberg M; Willett J; Hair E; Vallone D
Nicotine Tob Res; 2020 Apr; 22(5):843-847. PubMed ID: 30312465
[TBL] [Abstract][Full Text] [Related]
18. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
Waxman H; Corr B; Martin K; Duong S
Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
[TBL] [Abstract][Full Text] [Related]
19. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
Rulis AM; Levitt JA
Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
[TBL] [Abstract][Full Text] [Related]
20. A Roundtable Discussion: Combination Products: Twice the Challenge?
Baird N; Binion SB; Cammack J; Paine SD; Gonzales R; Passut J; Weiner JB
Biomed Instrum Technol; 2015; 49(5):322-9. PubMed ID: 26443908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
